BR112016005912A2 - sequência de ácido nucleico de cadeia leve de imunoglobulina recombinante, animal não humano geneticamente modificado, métodos para gerar um anticorpo e uma proteína de ligação e para produzir um animal não humano, célula ou tecido, vetor de alvejamento, proteína de ligação, e, ácido nucleico - Google Patents
sequência de ácido nucleico de cadeia leve de imunoglobulina recombinante, animal não humano geneticamente modificado, métodos para gerar um anticorpo e uma proteína de ligação e para produzir um animal não humano, célula ou tecido, vetor de alvejamento, proteína de ligação, e, ácido nucleicoInfo
- Publication number
- BR112016005912A2 BR112016005912A2 BR112016005912A BR112016005912A BR112016005912A2 BR 112016005912 A2 BR112016005912 A2 BR 112016005912A2 BR 112016005912 A BR112016005912 A BR 112016005912A BR 112016005912 A BR112016005912 A BR 112016005912A BR 112016005912 A2 BR112016005912 A2 BR 112016005912A2
- Authority
- BR
- Brazil
- Prior art keywords
- human animal
- binding protein
- light chain
- immunoglobulin light
- antibody
- Prior art date
Links
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 title abstract 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 title abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 title 2
- 108091008324 binding proteins Proteins 0.000 title 2
- 239000002253 acid Substances 0.000 title 1
- 150000007523 nucleic acids Chemical group 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
- 108020004705 Codon Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 210000004602 germ cell Anatomy 0.000 abstract 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
um animal não humano geneticamente modificado é fornecido, em que o animal não humano expressa um repertório de anticorpos capaz de ligação dependente de ph a antígenos quando de imunização. um animal não humano geneticamente modificado é fornecido que expressa domínios variáveis de cadeia leve de imunoglobulina humana derivados de um repertório limitado de segmentos de genes variáveis de cadeia leve de imunoglobulina humana que compreendem modificações de histidina em sua sequência de linhagem germinal. os métodos de produção dos animais não humanos que expressam anticorpos compreendendo resíduos de histidina codificados por códons de histidina introduzidos nas sequências de nucleotídeos de cadeia leve de imunoglobulina são fornecidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/030,424 US20140013456A1 (en) | 2012-03-16 | 2013-09-18 | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| PCT/US2014/056285 WO2015042250A1 (en) | 2013-09-18 | 2014-09-18 | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016005912A2 true BR112016005912A2 (pt) | 2017-09-26 |
Family
ID=51663490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016005912A BR112016005912A2 (pt) | 2013-09-18 | 2014-09-18 | sequência de ácido nucleico de cadeia leve de imunoglobulina recombinante, animal não humano geneticamente modificado, métodos para gerar um anticorpo e uma proteína de ligação e para produzir um animal não humano, célula ou tecido, vetor de alvejamento, proteína de ligação, e, ácido nucleico |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP3549437B1 (pt) |
| JP (3) | JP6621750B2 (pt) |
| KR (2) | KR102150414B1 (pt) |
| CN (2) | CN111019953A (pt) |
| AU (2) | AU2014323527B2 (pt) |
| BR (1) | BR112016005912A2 (pt) |
| CA (1) | CA2922892C (pt) |
| CY (1) | CY1121798T1 (pt) |
| DK (1) | DK3046412T3 (pt) |
| ES (2) | ES2962489T3 (pt) |
| HR (1) | HRP20191233T1 (pt) |
| HU (1) | HUE044747T2 (pt) |
| IL (2) | IL244226B (pt) |
| LT (1) | LT3046412T (pt) |
| MX (1) | MX362904B (pt) |
| MY (1) | MY191512A (pt) |
| PL (1) | PL3046412T3 (pt) |
| PT (1) | PT3046412T (pt) |
| RS (1) | RS59003B1 (pt) |
| RU (2) | RU2019121863A (pt) |
| SG (2) | SG11201601272YA (pt) |
| SI (1) | SI3046412T1 (pt) |
| SM (1) | SMT201900487T1 (pt) |
| TR (1) | TR201909967T4 (pt) |
| WO (1) | WO2015042250A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG192945A1 (en) | 2011-02-25 | 2013-09-30 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc antibody |
| WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| HK1198771A1 (en) | 2011-11-30 | 2015-06-05 | 中外制药株式会社 | Drug containing carrier into cell for forming immune complex |
| EP3721900A1 (en) | 2012-08-24 | 2020-10-14 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc region variant |
| WO2014104165A1 (ja) | 2012-12-27 | 2014-07-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| KR102318483B1 (ko) | 2013-04-02 | 2021-10-27 | 추가이 세이야쿠 가부시키가이샤 | Ｆｃ영역 개변체 |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用 |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| TWI831965B (zh) | 2016-08-05 | 2024-02-11 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
| WO2019098212A1 (en) | 2017-11-14 | 2019-05-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| CR20210127A (es) | 2018-08-10 | 2021-04-19 | Chugai Pharmaceutical Co Ltd | Molécula de unión al antigeno anti grupo de diferenciación 137 (cd137) y su uso |
| EP3897117A1 (en) * | 2018-12-21 | 2021-10-27 | Compass Therapeutics LLC | Transgenic mouse expressing common human light chain |
| KR20220116490A (ko) * | 2019-12-18 | 2022-08-23 | 브리스톨-마이어스 스큅 컴퍼니 | 공통 리더 서열을 갖는 bcr 트랜스제닉 마우스 |
| KR20230066386A (ko) | 2020-09-11 | 2023-05-15 | 리제너론 파마슈티칼스 인코포레이티드 | 항원 특이적 항체의 확인 및 제조 |
| CA3199879A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| CN114568343B (zh) * | 2022-03-11 | 2023-04-07 | 成都合拓创展生物科技有限公司 | 制备眼病模型的头具及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| PL1802193T3 (pl) | 2004-10-19 | 2014-09-30 | Regeneron Pharma | Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej |
| EP2003960B1 (en) * | 2006-03-31 | 2015-06-10 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| EP2374818B1 (en) | 2006-06-02 | 2012-12-19 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
| BRPI0911431B8 (pt) | 2008-04-11 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | composição farmacêutica compreendendo um antígeno e método para aumentar o número de antígenos que podem ser ligados por um anticorpo |
| JP2012508022A (ja) * | 2008-11-06 | 2012-04-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 減少した免疫原性を有する操作された抗体および作製方法 |
| CN103833855A (zh) | 2009-06-26 | 2014-06-04 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
| CA2767957C (en) | 2009-07-16 | 2020-08-25 | Wageningen Universiteit | Regulation of zinc deficiency and tolerance in plants |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| SG182647A1 (en) * | 2010-01-21 | 2012-08-30 | Oxyrane Uk Ltd | Methods and compositions for displaying a poypeptide on a yeast cell surface |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| MX378870B (es) | 2010-02-08 | 2025-03-11 | Regeneron Pharma | Raton de cadena ligera comun. |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| NZ602220A (en) * | 2010-03-11 | 2014-10-31 | Rinat Neuroscience Corp | Antibodies with ph dependent antigen binding |
| ME02440B (me) * | 2010-06-22 | 2016-09-20 | Regeneron Pharma | Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom |
| PL2640742T3 (pl) * | 2010-11-19 | 2019-01-31 | Morphosys Ag | Kolekcja sekwencji przeciwciał i jej zastosowanie |
| CA3186007A1 (en) * | 2011-09-30 | 2013-04-04 | Chugai Seiyaku Kabushiki Kaisha | Ion concentration-dependent binding molecule library |
| US20140013456A1 (en) * | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| JP5993102B2 (ja) * | 2013-02-20 | 2016-09-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 修飾された免疫グロブリン重鎖配列を有する非ヒト動物 |
-
2014
- 2014-09-18 CN CN201911266988.5A patent/CN111019953A/zh active Pending
- 2014-09-18 SG SG11201601272YA patent/SG11201601272YA/en unknown
- 2014-09-18 SI SI201431271T patent/SI3046412T1/sl unknown
- 2014-09-18 ES ES19159475T patent/ES2962489T3/es active Active
- 2014-09-18 MX MX2016003638A patent/MX362904B/es active IP Right Grant
- 2014-09-18 SG SG10201810825YA patent/SG10201810825YA/en unknown
- 2014-09-18 KR KR1020167009721A patent/KR102150414B1/ko not_active Expired - Fee Related
- 2014-09-18 PL PL14781761T patent/PL3046412T3/pl unknown
- 2014-09-18 RS RS20190873A patent/RS59003B1/sr unknown
- 2014-09-18 KR KR1020207024599A patent/KR20200103882A/ko not_active Ceased
- 2014-09-18 CA CA2922892A patent/CA2922892C/en active Active
- 2014-09-18 CN CN201480061443.XA patent/CN105722387B/zh active Active
- 2014-09-18 EP EP19159475.3A patent/EP3549437B1/en active Active
- 2014-09-18 BR BR112016005912A patent/BR112016005912A2/pt not_active IP Right Cessation
- 2014-09-18 HU HUE14781761 patent/HUE044747T2/hu unknown
- 2014-09-18 RU RU2019121863A patent/RU2019121863A/ru unknown
- 2014-09-18 MY MYPI2016700599A patent/MY191512A/en unknown
- 2014-09-18 JP JP2016543984A patent/JP6621750B2/ja active Active
- 2014-09-18 WO PCT/US2014/056285 patent/WO2015042250A1/en active Application Filing
- 2014-09-18 RU RU2016114306A patent/RU2694728C2/ru active
- 2014-09-18 HR HRP20191233TT patent/HRP20191233T1/hr unknown
- 2014-09-18 TR TR2019/09967T patent/TR201909967T4/tr unknown
- 2014-09-18 SM SM20190487T patent/SMT201900487T1/it unknown
- 2014-09-18 AU AU2014323527A patent/AU2014323527B2/en active Active
- 2014-09-18 LT LTEP14781761.3T patent/LT3046412T/lt unknown
- 2014-09-18 EP EP14781761.3A patent/EP3046412B1/en active Active
- 2014-09-18 ES ES14781761T patent/ES2738679T3/es active Active
- 2014-09-18 DK DK14781761.3T patent/DK3046412T3/da active
- 2014-09-18 PT PT14781761T patent/PT3046412T/pt unknown
-
2016
- 2016-02-22 IL IL244226A patent/IL244226B/en active IP Right Grant
-
2019
- 2019-01-16 JP JP2019004905A patent/JP2019068850A/ja not_active Withdrawn
- 2019-01-21 IL IL264358A patent/IL264358A/en unknown
- 2019-07-10 CY CY20191100728T patent/CY1121798T1/el unknown
-
2020
- 2020-03-03 JP JP2020035905A patent/JP2020078350A/ja not_active Withdrawn
-
2021
- 2021-01-15 AU AU2021200228A patent/AU2021200228A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016005912A2 (pt) | sequência de ácido nucleico de cadeia leve de imunoglobulina recombinante, animal não humano geneticamente modificado, métodos para gerar um anticorpo e uma proteína de ligação e para produzir um animal não humano, célula ou tecido, vetor de alvejamento, proteína de ligação, e, ácido nucleico | |
| CY1125196T1 (el) | Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii | |
| NZ627977A (en) | Humanized rodents that express heavy chains containing vl domains | |
| CY1122036T1 (el) | Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα | |
| CY1121545T1 (el) | Ποντικοι που εκφραζουν περιορισμενο ρεπερτοριο ελαφριων αλυσιδων ανοσοσφαιρινης | |
| CY1120599T1 (el) | Αντισωματα ελαφριων αλυσιδων τροποποιημενων με ιστιδινη και γενετικα τροποποιημενα τρωκτικα για τη δημιουργια αυτων | |
| BR112015019350A2 (pt) | Animal não humano, locus de imunoglobulina, e, métodos de fabricação de um animal não humano, para a obtenção de uma sequência de ácido nucleico e de fabricação de uma proteína de ligação ao antígeno | |
| MX2015012540A (es) | Ratón de cadena ligera común. | |
| BR112016021572A2 (pt) | Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação | |
| CY1121869T1 (el) | Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας | |
| HK1208994A1 (en) | Methods for making fully human bispecific antibodies using a common light chain | |
| BR112014008775A8 (pt) | Métodos para produzir camundongos com locus restrito de cadeia pesada de imunoglobulina, para obter célula ou tecido de camundongos, para produzir sequência de ácido nucleico que codifica domínio variável de cadeia pesada humano, bem como ácido nucleico | |
| WO2013041845A3 (en) | Animals, repertoires & methods for the production of human antibodies | |
| NZ703689A (en) | Humanized non-human animals with restricted immunoglobulin heavy chain loci | |
| MX353278B (es) | Raton con cadena ligera comun. | |
| MX384418B (es) | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido. | |
| HK1250038A1 (zh) | 選擇結合抗原的輕鏈可變區的非人動物 | |
| EA201790236A1 (ru) | Антитела против vasa и способы их получения и использования | |
| AU2012315616A8 (en) | Identification of antigen-specific adaptive immune responses using Arm-PCR and high-throughput sequencing | |
| CY1118707T1 (el) | Her2 dna εμβολιο ως συμπληρωματικη αγωγη για καρκινους σε ζωα συντροφιας | |
| DOP2020000005A (es) | ANTICUERPOS CONTRA MAdCAM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2688 DE 12-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |